Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

12 Pages (Click to Jump) V  < 1 2 3 4 5 6 7 > »    
 
  
Reply to this topic

CGS, COGSTATE LTD
Opeth
post Posted: Apr 13 2006, 10:16 AM
  Quote Post


Posts: 167
Thanks: 1


In reply to: Opeth on Wednesday 12/04/06 07:03pm

look at this small beauty:)


cool.gif

30c on the way

 
Opeth
post Posted: Apr 12 2006, 07:03 PM
  Quote Post


Posts: 167
Thanks: 1


In reply to: mme on Wednesday 12/04/06 10:23am

any news on the way?

don't understand why so small volume made average 10% stock price up almost everyday.

 
mme
post Posted: Apr 12 2006, 10:23 AM
  Quote Post


Posts: 8,077
Thanks: 429


In reply to: Opeth on Tuesday 11/04/06 09:24pm

Yep I shouldn't been so impatient!! Would of been on 100% plus profit!! biggrin.gif

 
Opeth
post Posted: Apr 11 2006, 09:24 PM
  Quote Post


Posts: 167
Thanks: 1


In reply to: tilford on Tuesday 11/04/06 07:31am

Another good day for CGS

very small turnover with 10% sp pick up.

We can image with huge turnover how this tiny stock will fly:)

 
tilford
post Posted: Apr 11 2006, 07:31 AM
  Quote Post


Posts: 485


In reply to: Opeth on Tuesday 11/04/06 02:00am


Article


Psychopharmacology
Publisher: Springer Berlin / Heidelberg
ISSN: 0033-3158 (Paper) 1432-2072 (Online)
DOI: 10.1007/s00213-006-0331-5
Issue: Online First
Original Investigation
A statistical approach for classifying change in cognitive function in individuals following pharmacologic challenge: an example with alprazolam

Paul Maruff1 Contact Information, John Werth2, Bruno Giordani3, Angela F. Caveney3, Douglas Feltner2 and Peter J. Snyder4
(1) CogState Ltd, Melbourne, Australia
(2) CNS Early Development, Pfizer Global Research & Development, Ann Arbor, MI, USA
(3) Section of Neuropsychology, Department of Psychiatry, University of Michigan School of Medicine, Ann Arbor, MI, USA
(4) Department of Psychology, University of Connecticut (Storrs, CT) & CNS Early Development, Pfizer Global Research & Development, Groton, CT, USA

Received: 8 June 2005 Accepted: 16 January 2006 Published online: 28 March 2006
Abstract
Introduction The effects of any drug treatment on cognitive function are typically studied in groups of subjects. Observations made about the behavior of the drug, in the study sample, are then generalized to the population from which the sample was drawn. However, the magnitude and pharmacodynamic qualities of the response to many central nervous system-active drugs are known to vary in the population. Therefore, it is useful to consider statistical models for the detection of cognitive change in response to a drug treatment in individual subjects.
Materials and methods In this report, we first outline the statistical assumptions and requirements for the reliable estimation of clinically relevant individual change in cognition. We then used the sedative benzodiazepine, alprazolam, as a pharmacologic challenge in healthy volunteer subjects to test our statistical model, using a parallel groups placebo-controlled study design. After treatment, the nature and severity of alprazolam-induced cognitive change was determined for each individual.
Results Our proposed method and analysis showed an excellent sensitivity and specificity for alprazolam-related cognitive deterioration in individuals.
Discussion and conclusions These findings, although preliminary, suggest that statistically reliable decisions about the effects of sedative drugs on cognition can be made for individuals.

Contact Information Paul Maruff

 
Opeth
post Posted: Apr 11 2006, 02:00 AM
  Quote Post


Posts: 167
Thanks: 1


In reply to: Opeth on Tuesday 11/04/06 01:58am

found from official website

cogstate.com/index.php?newsID=954

worth a read

the project initial result funded by Giant Pfizer:)

 


Opeth
post Posted: Apr 11 2006, 01:58 AM
  Quote Post


Posts: 167
Thanks: 1


In reply to: tilford on Monday 10/04/06 06:44pm

i think the investors will see a very positive quaterly report on the way.

small volume push this tiny stock back to 20cents.

If any huge turnover happened, this stock will be the shining stock in the biotech sector

 
tilford
post Posted: Apr 10 2006, 06:44 PM
  Quote Post


Posts: 485


In reply to: crystal on Monday 10/04/06 03:09pm

Maple-Brown Abbott took 7% interest (3.262,936 shares)
Rivkin tended to take interest when MBA was buying.......worth watching!

 
crystal
post Posted: Apr 10 2006, 03:09 PM
  Quote Post


Posts: 1,636
Thanks: 45


In reply to: mme on Monday 10/04/06 03:23pm

me too sadsmiley02.gif

mick

 
mme
post Posted: Apr 10 2006, 02:23 PM
  Quote Post


Posts: 8,077
Thanks: 429


In reply to: Opeth on Wednesday 05/04/06 06:13pm

Yep looks like I sold out of this one too early!!! grrr.gif biggrin.gif

 
 


12 Pages (Click to Jump) V  < 1 2 3 4 5 6 7 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING